Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Jnj crawled time : 20:20 save search
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
Published: 2024-03-09 (Crawled : 20:20) - prnewswire.com
PTGX | $25.57 -2.07% -2.19% 520K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
jnj-2113 first year psoriasis one clearance skin
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2023-06-03 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
response results study
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Published: 2023-06-03 (Crawled : 20:20) - prnewswire.com
GMAB | $28.53 -3.06% -3.23% 310K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $281.02 -1.44% 3.83% 210
|
Health Technology
| Email alert
Add to watchlist
response
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
Published: 2023-04-30 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
|
| O: -0.06%
H: 0.43%
C: 0.0%
tar-200 antibody bladder cancer results study
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Published: 2023-03-04 (Crawled : 20:20) - prnewswire.com
PVBC | $7.76 -0.13% 0.13% 63K
|
Finance
| Email alert
Add to watchlist
FATE | $5.27 -2.05% -1.89% 2.1M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
trial deadline
Global Men's Grooming Products Market Report 2022: A $57.2 Billion Industry in 2021 - Forecasts to 2028 Featuring P&G, Estee Lauder, Unilever, J&J, & Coty Among Others
Published: 2023-01-22 (Crawled : 20:20) - prnewswire.com
PHG | News | $20.15 -0.89% -0.6% 740K
|
Health Technology
|
| O: 1.51%
H: 3.28%
C: 2.92%
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
|
| O: 0.21%
H: 0.31%
C: -0.47%
EPC 4 | $35.32 -0.4% 0.0% 250K
|
Consumer Non-Durables
|
| O: 0.12%
H: 0.47%
C: -1.68%
COTY | $10.63 -1.85% 0.0% 3.5M
|
Consumer Non-Durables
|
| O: 0.0%
H: 0.58%
C: 0.53%
global report market
Insights on the Atrial Fibrillation Global Market to 2028: by End-user, Type, Technology and Region
Published: 2023-01-21 (Crawled : 20:20) - prnewswire.com
MDT | News | $79.08 -0.22% 0.25% 4.6M
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $105.9 -3.03% 0.38% 11M
|
Health Technology
| Email alert
Add to watchlist
ATRC | $23.45 1.52% 1.53% 550K
|
Health Technology
| Email alert
Add to watchlist
BSX | $67.96 -0.24% -0.49% 6.2M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
PHG | News | $20.15 -0.89% -0.6% 740K
|
Health Technology
| Email alert
Add to watchlist
global technology market
$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 - Featuring Amgen, Biocon, Dr. Reddy's Laboratories and Intas Pharmaceuticals Among Others
Published: 2023-01-21 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
| Email alert
Add to watchlist
pharmaceuticals
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
faspro darzalex trial
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
FATE | $5.27 -2.05% -1.89% 2.1M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
meeting therapeutics
Janssen Joins Forces with Pro Football Hall-of-Famer Shannon Sharpe to Address Health Disparities in Prostate Cancer
Published: 2022-09-18 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
health cancer prostate cancer
2022 New Jersey 'Walk with Us to Cure Lupus' Raises Awareness and Funds for Commonly Misdiagnosed Autoimmune Disease
Published: 2022-05-14 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
disease
Aspen presented with 2022 Economic Diplomacy (Global) Ubuntu Award
Published: 2022-02-12 (Crawled : 20:20) - aspenpharma.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
awards
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $281.02 -1.44% 3.83% 210
|
Health Technology
| Email alert
Add to watchlist
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
| Email alert
Add to watchlist
GMAB | $28.53 -3.06% -3.23% 310K
|
Health Technology
| Email alert
Add to watchlist
results antibody
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
Published: 2021-12-05 (Crawled : 20:20) - globenewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
phase 2 covid positive phase 2 results results topline vaccine covid-19
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2021
Published: 2021-06-05 (Crawled : 20:20) - akaritx.com
FBRX 4 | $0.74 0.87% 4.69% 57K
|
Health Technology
| Email alert
Add to watchlist
ATEC | News | $12.51 -5.16% -5.35% 970K
|
Health Technology
| Email alert
Add to watchlist
DB | $15.67 1.95% -0.38% 8.4M
|
Finance
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.